Oxford University/AstraZeneca vaccine authorised by UK medicines regulator

The government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise Oxford University/AstraZeneca’s COVID-19 vaccine for use.

https://www.gov.uk/government/news/oxford-universityastrazeneca-vaccine-authorised-by-uk-medicines-regulator

More than 137,000 people in UK receive first dose of COVID vaccine in one week

More than 137,000 people in the UK have received the first dose of the Pfizer/BioNTech COVID-19 vaccine in the first week of the largest vaccination programme in British history.

https://www.gov.uk/government/news/more-than-137000-people-in-uk-receive-first-dose-of-covid-vaccine-in-one-week

The Sputnik V vaccine’s efficacy is confirmed at 91.4% based on data analysis of the final control point of clinical trials

The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), announce the efficacy of over 90% of the Russian Sputnik V vaccine as demonstrated by the final control point data analysis of the largest double-blind, randomized, placebo-controlled Phase III post-registration clinical trials of the Sputnik V vaccine against novel coronavirus infection in Russia’s history.

https://sputnikvaccine.com/newsroom/pressreleases/the-sputnik-v-vaccine-s-efficacy-is-confirmed-at-91-4-based-on-data-analysis-of-the-final-control-po/

FDA Issues Emergency Use Authorization for First COVID-19 Vaccine

Today, the U.S. Food and Drug Administration issued the first emergency use authorization (EUA) for a vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S.

https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19

UK authorises Pfizer/BioNTech COVID-19 vaccine

The government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer/BioNTech’s COVID-19 vaccine for use.

https://www.gov.uk/government/news/uk-authorises-pfizer-biontech-covid-19-vaccine

India’s 1st COVID-19 Vaccine - COVAXIN™, Developed by Bharat Biotech gets DCGI approval for Phase I & II Human Clinical Trials

Bharat Biotech has successfully developed COVAXIN™, India’s 1st vaccine candidate for COVID-19, in

collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The

indigenous, inactivated vaccine developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety

Level 3) High Containment facility located in Genome Valley, Hyderabad, India.

https://www.bharatbiotech.com/images/press/Indias-1st-COVID-19-Vaccine-COVAXIN-Developed-by-Bharat-Biotech-gets-DCGI-approval-for-Phase-I-and-II-Human-Clinical-Trials.pdf

Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints.

https://web.archive.org/web/20201118120708/https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-and-BioNTech-Conclude-Phase-3-Study-of-COVID-19-Vaccine-Candidate-Meeting-All-Primary-Efficacy-Endpoints/default.aspx